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A consensus meeting was held in Vienna on Septem-
ber 8–9, 2013, to discuss diagnostic and therapeutic
challenges surrounding development of diabetes
mellitus after transplantation. The International Expert
Panel comprised 24 transplant nephrologists, sur-
geons, diabetologists and clinical scientists, which
met with the aim to review previous guidelines in light
of emerging clinical data and research. Recommenda-
tions from the consensus discussions are provided in
this article. Although the meeting was kidney-centric,
reflecting the expertise present, these recommenda-
tions are likely to be relevant to other solid organ
transplant recipients. Our recommendations include:
terminology revision from new-onset diabetes after
transplantation to posttransplantation diabetes melli-
tus (PTDM), exclusion of transient posttransplant
hyperglycemia from PTDM diagnosis, expansion of
screening strategies (incorporating postprandial glu-
cose and HbA1c) and opinion-based guidance regard-
ing pharmacological therapy in light of recent clinical
evidence. Future research in the field was discussed
with the aim of establishing collaborative working
groups to address unresolved questions. These rec-
ommendations are opinion-based and intended to
serve as a template for planned guidelines update,
based on systematic and graded literature review, on
the diagnosis and management of PTDM.
Abbreviations: AGM, afternoon glucose monitoring;
CNI, calcineurin inhibitor; GRADE, Grading of Recom-
mendations Assessment, Development and Evaluation;
NODAT, new-onset diabetes after transplantation;
OGTT, oral glucose tolerance test; PTDM, posttransplan-
tation diabetes mellitus
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Introduction
Previously published consensus guidelines on the diagno-
sis and management of diabetes mellitus after transplanta-
tion acknowledged the importance of posttransplant
diabetes in all forms of solid organ transplantation and
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the need for pro-active, multi-disciplinary manage-
ment (1,2). As these were based on conferences held a
decade ago, an International Expert Panel of clinicians/
researchers was recently convened (Vienna, Austria,
September 8–9, 2013) with two objectives: (1) update
previous consensus statements and (2) debate current
gaps in our clinical evidence base. The panel comprised 24
transplant clinicians, diabetologists and scientists with an
active interest in the field. Invitations were based upon a
meeting prerequisite to systematically review existing
literature for presentation at an open scientific session,
encouraging debate and discussion (3). This session
contributed to the proceedings of the subsequent closed
meeting of the International Expert Panel the following day.
While the focus was on kidney transplantation, reflecting
the published literature, the principles are likely relevant to
all forms of solid organ transplantation.
This Meeting Report summarizes our major recommenda-
tions from the consensusmeeting, with quality of evidence
graded in line with GRADE (Grading of Recommendations
Assessment, Development and Evaluation) definitions (4).
GRADE provides a systematic approach to grade quality of
evidence and strength of recommendations. Consensus
opinion was to provide the following recommendations:
high (Recommendation 4), moderate (Recommendations
2, 3, 5 and 6) and none possible (Recommendation 1 and 7).
Readers requiring comprehensive literature reviews as
background information are recommended recent publica-
tions in this area (5,6). It is anticipated these opinion-based
recommendations will form the template for a planned
comprehensive update to existing guidelines.
Recommendation 1: Change Terminology
From New-Onset Diabetes After
Transplantation Back to
Posttransplantation Diabetes Mellitus
(PTDM)
The term new-onset diabetes after transplantation (NO-
DAT) was adopted to acknowledge the pathophysiological
consequences of transplantation on glycemic metabolism.
However, the termmay be misleading, as diabetes is often
unrecognized (7,8). The term NODAT implies exclusion of
diabetes prior to transplantation, but effective pretransplant
screening is impractical for many centers.
The term posttransplantation diabetes mellitus (PTDM)
addresses these shortcomings by simply describing newly
diagnosed diabetes mellitus in the posttransplantation
setting (irrespective of timing or whether it was present
but undetected prior to transplantation or not). The term
PTDM should be utilized for clinically stable patients who
have developed persistent posttransplantation hyperglyce-
mia (see Table 1). The term prediabetes should be utilized
for patients with posttransplantation hyperglycemia not
reaching diagnostic thresholds for PTDM (impaired fasting
glucose and/or impaired glucose tolerance) (Table 1).
Fasting glucose has a low sensitivity for diagnosing
PTDM, as kidney allograft recipients have relatively
preserved fasting glucose concentrations after an oral
glucose tolerance test (OGTT) (9–11). Consequently,
lowering the threshold for impaired fasting glucose in the
screening for PTDM seems appropriate and the American
Diabetes Association cutoff (5.6mmol/L [100mg/dL])
was preferred over the World Health Organization cutoff
(6.1mmol/L [110mg/dL]). These updated terms are utilized
for the rest of this report.
Recommendation 2: Exclude Transient
Posttransplantation Hyperglycemia From
PTDM Diagnosis
Hyperglycemia is exceptionally common in the early
posttransplant period, detectable in approximately 90%
of kidney allograft recipients in the early fewweeks (12,13).
Hyperglycemia can also occur as a consequence of
rejection therapy, infections and other critical conditions.
While identifying transient posttransplantation hyperglyce-
mia is important, being an important risk factor for
subsequent PTDM (14), ubiquitously labeling the majority
of kidney allograft recipients with PTDM in the immediate
posttransplant setting is not helpful. A formal diagnosis
of PTDM is best made when patients are stable on their
likely maintenance immunosuppression, with stable kidney
allograft function and in the absence of acute infections.
Recommendation 3: Expand Screening
Tests for PTDM Using Postprandial Glucose
Monitoring and HbA1c to Raise Suspicion,
While Oral Glucose Tolerance Tests Remain
the Most Important
The transplant community lacks data linking glycemic
parameters with long-term macrovascular (e.g. myocardial
infarct, stroke) and microvascular (e.g. retinopathy, ne-
phropathy) complications, remaining dependent on out-
come studies from the nontransplant population (15). As no
glycemic indicator posttransplantation has demonstrated
superiority with regard to long-term outcomes, the optimal
measure remains unclear. At present, the OGTT is
considered the gold standard for diagnosing PTDM. OGTTs
identify more patients with diabetes posttransplantation
than fasting glucose measurement alone (9–11), a similar
observation to the general population, but detection is
higher due to different pathophysiology between PTDM
and type 2 diabetes (6,16). An OGTT also allows diagnosis
of impaired glucose tolerance to be made, which is an
independent risk factor for long-term development of
PTDM, cardiovascular disease and mortality when tested
either before (17) or after transplantation (18,19). However,
OGTTs are not widely used as they are time consuming and
impractical in a large transplant program.
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HbA1c-based diagnosis is endorsed for diagnosis of
diabetes mellitus in the general population (20) and we
recommend elevated HbA1c be used to recognize PTDM
(see Table 1). Caution must be exercised with its use early
posttransplantation, as a normal HbA1c will not exclude
diagnosis in the presence of posttransplantation anemia
and/or dynamic renal allograft function (21). However,
HbA1c 5.7–6.4% or higher in this early period would
indicate the need to follow up with a recognized diagnostic
test, although HbA1c greater than 6.5% is unlikely to be
a false positive. Shabir et al (22) suggest optimum HbA1c
cut-off values for predicting PTDM at 3 and 12 months of
44mmol/mol (6.2%) and 48mmol/mol (6.5%), respectively
(latter equivalent to general population), but this analysis
was based on a small cohort of 71 kidney allograft recipients
and requires further validation.
Yates et al (23) recently reported afternoon glucose
monitoring (AGM) in kidney allograft recipients, using
capillary blood glucose, was more sensitive to both OGTT
and HbA1c for detecting hyperglycemia in the initial 6-week
posttransplant period in patients on corticosteroid contain-
ing regimens. However, this approach has not been
validated for diagnosis of PTDM. Thus, testing for AGM
in the early postoperative period may better identify
individuals who should receive an OGTT or other recog-
nized diagnostic testing.
The use of screening strategies should help to streamline
diagnosis of PTDM, through identification of a subset of
high-risk patients who should undergo further testing. One
study demonstrated the benefit of a screening algorithm
based upon fasting glucose and/or HbA1c, thereby reduc-
ing overall number of OGTTs required (9). The superiority
of this streamlined approach over more widespread OGTT
testing for PTDM remains to be determined.
Surveillance for glycemic abnormalities pretransplantation,
including OGTT when possible, will help identify patients
who have undiagnosed diabetes (8) or prediabetes (17).
Studies have shown the utility of glucose-based diagnostic
criteria pretransplantation (8), but using HbA1c is fraught
with difficulty in patients with severe renal impairment or
end-stage kidney disease. Kidney transplant candidates
should have an annual check of glycemic status, either in
the form of fasting glucose or risk-stratified OGTT (based
upon center-specific screening algorithm). However, evi-
dence is insufficient to recommend OGTTs for all kidney
transplant candidates unless it forms part of a risk-stratified
algorithm (8).
Recommendation 4: Identify Patients at
Risk for PTDM
Risk factors for PTDM are well established (24), encom-
passing both general (e.g. age, family history of diabetes,
prior history of glucose intolerance (25)) and transplant-
specific (e.g. immunosuppression) factors, with accruing
risk factors associated with greater PTDM risk. Novel
targets continue to be identified, incorporating an improved
understanding of metabolic syndrome and identification
of select genetic polymorphisms as PTDM risk factors.
Israni et al (26) found posttransplant metabolic syndrome
independently associated with subsequent risk of PTDM.
When occurring pretransplantation, the metabolic syn-
drome (27) and its components such as pretransplant
hypertriglyceridemia and BMI (28), as well as prediabe-
tes (17) have predicted increased risk for PTDM. Specifi-
cally pretransplantation insulin resistance, putatively the
underlying pathophysiology of metabolic syndrome, was
found to be a risk factor for PTDM (7).
Pancreatic beta cell dysfunction (reflected by high fasting
proinsulin concentrations) has been shown to be a risk
factor for PTDM (29) and these data are supported by
genetic polymorphism studies. Kim et al (30) identified
an association between single nucleotide polymorphisms
within 10 genes of interleukins or their receptors as
predictors of PTDM. Similarly, Tavira et al (31) demonstrat-
ed an association between KNNJ11 polymorphisms,
hypothesized to impair insulin release from pancreatic
beta cells, and PTDM.
Table 1: Diagnostic criteria for diabetes mellitus and prediabetes by the American Diabetes Association (ADA)
ADA1
Diabetes mellitus Symptoms of diabetes plus RPG200mg/dL (11.1mmol/L) OR FPG126mg/dL (7.0mmol/L)
OR 2HPG200mg/dL (11.1mmol/L) during an OGTT OR HbA1c6.5%
Prediabetes
Impaired fasting glucose FPG 100–126mg/dL (5.6–6.9mmol/L)
Impaired glucose tolerance FPG<7.0mmol/L AND 2HPG 7.8–11.0mmol/L
Increased risk of diabetes HbA1c 5.7–6.4%
Normal glucose tolerance FPG<110mg/dL (5.6mmol/L) AND 2HPG<140mg/dL (7.8mmol/L) AND HbA1c<5.7%
RPG, random plasma glucose; FPG, fasting plasma glucose; 2HPG, 2-h plasma glucose after an oral glucose.
1A confirmatory laboratory test based onmeasurements of venous plasma glucosemust be done on any subsequent day in the absence of
unequivocal hyperglycemia accompanied by acute metabolic decompensation. Symptoms of diabetes include polyuria, polydipsia and
unexplained weight loss. Random plasma glucose is defined as any time of day without regard to time since last meal. Fasting is defined as
no caloric intake for at least 8 h. The oral glucose tolerance test should be performed using a glucose load of 75 g anhydrous glucose
dissolved in water.
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Screening for posttransplant glucose abnormalities (Rec-
ommendation 3) is even more important in those patients
identified to be at a higher risk of PTDM. In a prospective
cohort of over 600 patients undergoing serial OGTTs,
the vast majority of late PTDM were prediabetic at
3 months (32). Trials are needed to determine whether
modifying established or novel risk factors can attenuate
progression to PTDM.
Recommendation 5: Choose and Use
Immunosuppression Regimens Shown to
Have the Best Outcome for Patient and
Graft Survival, Irrespective of PTDM Risk
Immunosuppression is the major modifiable risk factor for
development of PTDM but risk versus benefit analysis
is required to balance risk of developing PTDM versus
rejection. Cole et al (33) demonstrated adverse graft
survival after development of either rejection or PTDM,
with development of both resulting in the worst outcomes.
Therefore, no specific recommendation is made to advo-
cate a definitive immunosuppressant strategy for allograft
recipients based upon PTDM risk alone. Based on the
current lack of evidence we also recommend caution in
immunosuppressant adjustments in the event that PTDM
develops, with a need to account for patient-specific risk
factors such as immunological risk.
The DIRECT study confirmed the increased diabetogenicity
of tacrolimus compared to cyclosporine postkidney trans-
plantation in a randomized controlled trial, with no
difference in adverse events (34). However, this was a
6-month trial and glycemic benefits need to be weighed
against risk for long-term graft attrition. In addition, target
tacrolimus levels were higher than the contemporary
approach of reduced calcineurin inhibitor (CNI) exposure.
A recent meta-analysis of 56 randomized controlled trials
demonstrated less PTDM and better overall graft survival
with CNI-minimization or avoidance strategies using new
agents such as belatacept or tofacitinib (35). Results are
awaited from groups evaluating alternative strategies such
as selecting CNI (tacrolimus vs. cyclosporine) based on
pretransplant PTDM risk (clinicaltrials.org: NCT01002339).
There is limited evidence supporting conversion from
tacrolimus to cyclosporine in established PTDM, both
from previous literature (36) and a preliminary report of
randomized trial data (37), but the benefits must be
weighed against any risks associated with conversion.
Late changes in immunosuppressive regimens may
reverse PTDM without jeopardizing graft outcomes, but
this requires further evaluation to ensure glycemic benefits
outweigh allograft risks.
Johnston et al, analyzing data from the United States Renal
Data System, found sirolimus were independently associ-
ated with increased risk for PTDM (38). Fewer reports have
conflictingly found glycemic benefits after conversion from
CNIs to sirolimus (39). There is no evidence to suggest
any glycemic effects of anti-proliferative agents such as
mycophenolate mofetil or azathioprine.
Steroidminimization is a common strategy to attenuate risk
of PTDM. However, a beneficial effect of corticosteroid
sparing strategies has not been demonstrated (40). A
recent meta-analysis of corticosteroid withdrawal between
3 and 6 months after transplantation found no meaningful
effect on PTDM incidence (41). Early corticosteroid
withdrawal after a few days has shown decreased PTDM
incidence, but this was only significant when the CNI used
was cyclosporine compared to tacrolimus (42). Moreover, a
mild increase in the incidence of acute rejection with
corticosteroid sparing strategies might counterbalance the
metabolic beneficial effect (41). The degree of glycemic
burden from low-dose corticosteroid maintenance therapy
is unclear and therefore steroid avoidance/withdrawal
strategies require careful risk/benefit assessment in the
context of long-term outcomes. The impact of steroid
avoidance/withdrawal is all the more uncertain given the
current use of lower CNI target levels and rapid weaning of
corticosteroids. Split corticosteroid dosing may also reduce
glycemic variability and peak hyperglycemia (43).
Data in relation to the impact of induction therapy are
limited and no firm conclusions can be drawn. In a recent
meta-analysis of five studies (n¼ 492 patients), the mAb
alemtuzumab was found to be associated with a borderline
lower risk of developing PTDM than IL-2 receptor
antagonists (44). This could be due to CNI- and steroid-
sparing strategies employed with alemtuzumab use or a
diabetogenic effect of IL-2 receptor antagonists. Support-
ing the latter is a single-center retrospective study of
264 renal transplant recipients, where induction with
basiliximab was associated with a significantly greater
risk of developing PTDM compared to no induction (51.5%
vs. 36.9%, p¼ 0.017) at 10 weeks posttransplantation (45).
Recommendation 6: Use Strategies for
Prevention and Treatment Beyond
Modification of Immunosuppressive
Regimens
Prevention is ideal and guidance should be given to all
potential transplant recipients regarding their risk of
developing PTDM. Intervention when necessary can be
in the form of nonpharmacological and/or pharmacological
therapy. Sharif et al (46) demonstrated the potential for
benefit from lifestyle modification in kidney allograft
recipients with impaired glucose tolerance (13/25 patients
reverted to normal glucose tolerance after median of
9 months, with only 1 progressing to PTDM). Thus, as
observed in the general population (47), exercise and
lifestyle modification may reduce the risk of patients with
prediabetes developing PTDM. However, there remains
a need for well-powered clinical trials to evaluate the
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feasibility and efficacy of these interventions to prevent
PTDM in a larger renal transplant population. Werzowa
et al (48) reported a randomized controlled trial comparing
safety and efficacy of vildagliptin (dipeptidylpeptidase-4
inhibitor) with pioglitazone (thiazolidinedione) or placebo in
kidney allograft recipients with impaired glucose tolerance.
Adverse events were equivalent in all three arms and both
pioglitazone and vildagliptin produced comparable reduc-
tion in 2-h postprandial glucose levels. Metformin may
be an attractive anti-hyperglycemic agent to reduce the
likelihood of PTDM in high-risk individuals (49) but the
benefits of metformin need to be weighed against the risks
associated with metformin in the context of impaired renal
function (e.g. lactic acidosis). However, this association has
been the subject of critical analysis (50) and well-designed
clinical trials are necessary to shed light on the benefit
versus risk ratio in relation to metformin.
Lifestyle modification> oral anti-diabetic therapy> insulin
is an appropriate stepwise approach for management of
late-PTDM, but with immediate posttransplant hyperglyce-
mia we recommend the reverse as the most appropriate
management. Insulin is the only safe and effective agent
in the context of high glucocorticoid doses and acute
illness early posttransplant, but early and aggressive use
of insulinmay also have long-termbenefits. In a randomized
controlled trial, Hecking et al (12) demonstrated the benefit
of early basal insulin therapy following detection of early
posttransplant hyperglycemia (<3 weeks) at reducing
subsequent odds of developing PTDM within the first
year posttransplantation by 73%. A larger randomized
controlled clinical trial (ITP-NODAT, clinicaltrials.org:
NCT01683331) is currently evaluating whether these
findings are reproducible in five centers recruiting over
300 patients. In addition, this study will determine whether
early insulin therapy is feasible in patients who are
hospitalized for a much shorter period than utilized in the
original study. Treatment of posttransplantation hypergly-
cemia is in line with postoperative glucose management
and, although representing a major shift from previous
practice, consensus opinion was that this approach should
be recommended but a glucose threshold for starting
insulin was not specified (Figure 1). Although a relatively
high glucose threshold of 200mg/dL (evening or fasting)
has been previously suggested, it may be reasonable
to lower this threshold but further research is warranted
before firm guidance can be issued.
The armamentarium of anti-diabetic therapy is increasing
and individual pharmacological risk/benefit profiles must be
evaluated in the context of transplantation (5,6,20). Dose
adjustments or cessation of oral anti-diabetic agents in the
context of renal allograft dysfunction should be individual-
ized. Further work to understand the pathophysiology
underlying PTDM development and progression should
assist choice of pharmacological agents and form the basis
Figure 1: Flowchart highlighting updated diagnostic and management framework for posttransplantation diabetes mellitus.
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of targeted clinical trials. Haidinger et al (51) have recently
reported the first randomized controlled trial comparing
vildagliptin with placebo for treatment of PTDM, demon-
strating profound improvement in both 2-h postprandial
glucose andHbA1c levelswithin 3months. Halden et al (52)
have also reported the short-term efficacy and safety of
a different dipeptidylpeptidase-4 inhibitor (sitagliptin) in
their randomized crossover study of 19 kidney allograft
recipients with PTDM. Further clinical trials are warranted
to attain a clinical evidence-base for the optimum agent
or agent combinations for both safety and efficacy. For
example, there are no data regarding the safety and/or
efficacy of glucagon-like peptide 1 receptor agonists in the
context of kidney transplantation.
The consensus group agreed there were inadequate
data to recommend a hierarchy of anti-glycemic agents
in this setting (53). Previous reluctance to use metformin
posttransplantation was discussed in line with recent
arguments focusing on its advantages (49). A research
Table 2: Currently active PTDM-related research studies registered on clinicaltrials.org
Clinicaltrials.org
study identifier Study completion Title of research project Study narrative
NCT01680185 August 2017 Sensor-Augmented Insulin-Pump Therapy in
New-onset Diabetes After Transplantation
(SAPT-NODAT)
Open label RCT testing benefits of intensive
subcutaneous insulin via an insulin pump in
comparison to standard of care (basal insulin)
NCT01683331 August 2017 A Clinical Trial to Prevent New Onset
Diabetes After Transplantation
(ITP-NODAT)
Open label RCT testing benefits of early insulin
therapy for posttransplantation hyperglycemia in
first week post-op
NCT01875224 August 2016 Comparison of NODAT in Kidney Transplant
Patients Receiving Belatacept Versus
Standard Immunosuppression
Open label RCT comparing glycemic benefits
of de novo belatacept versus standard
tacrolimus-based therapy
NCT01002339 June 2013 Optimum Immunosuppression in Renal
Transplant Recipients. New Onset
Diabetes After Transplantation (01-DMPT)
Open label RCT analyzing benefits and risks with 3
different de novo regimens in glycemic high-risk
patients: (1) tacrolimus with rapid steroid
withdrawal, (2) tacrolimus with steroid
minimization, (3) cyclosporine with steroid
minimization
NCT01928199 June 2015 Efficacy Study of Sitagliptin to Prevent
New-Onset Diabetes After Kidney
Transplant
Double blind RCT testing benefits of adding
sitagliptin to preventing PTDM in recipient with
transient posttransplantation hyperglycemia in
first 72 h post-op
NCT01265537 December 2015 A Pilot Study Comparing the Use of
Low-Target Versus Conventional
Target Advagraf (Astellas)
Open label RCT comparing glycemic benefits of
standard tacrolimus-based therapy with low-
target tacrolimus regimen (þ thymoglobulin
inductionþearly steroid withdrawal)
NCT01856257 October 2015 Safety and Efficacy of a Steroid-Free,
Calcineurin Inhibitor-Free, Belatacept-
Based Immunosuppressive Regimen
Open label RCT comparing glycemic benefits of a
belatacept-based regimen (de novo or
conversion) against tacrolimus-based therapy
NCT01431430 June 2015 VITamin D Supplementation in RenAL
Transplant Recipients—VITALE
Double blind RCT to study the effect of low-dose
versus high-dose colecalciferol supplementation
on composite end point of PTDM, de novo
cancer, cardiovascular disease and mortality
NCT01648218 June 2013 Insulin Therapy for Posttransplant
Glucocorticoid Induced Hyperglycemia
(PTHG)
Open label RCT to study which insulin therapy
(NPH, Aspart or Glargine) is most effective to
posttransplant hyperglycemia over a 48-h
period during hospitalization for transplantation
(PTDM or type 2 diabetes mellitus)
NCT01291030 May 2013 The Impact of Magnesium Supplementation
on Insulin Resistance and Secretion in
Renal Transplant Recipients
Open label RCT to assess effect of magnesium
supplementation posttransplantation on insulin
resistance and secretion indices (OGTT)
NCT01560572 April 2015 Steroid Free Immunosuppression or
Calcineurin Inhibitor Minimization After
Basiliximab Induction Therapy in Kidney
Transplantation: Comparison With a
Standard Quadruple Immunosuppression
Regimen (Allegro)
Open label RCT investigating effects of steroid-free
immunosuppression versus tacrolimus
minimization at 6 months for secondary outcome
of PTDM at 2 years (primary outcome is acute
rejection and graft function)
RCT, randomized controlled trial; PTDM, posttransplantation diabetes mellitus; NPH, neutral protamine Hagedorn; OGTT, oral glucose
tolerance test.
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consortium of interested parties proposed a feasibility
study looking at early use of metformin therapy for kidney
allograft recipients. Clinical trials are warranted to assess
safety and efficacy beforemetformin can be recommended
as the anti-glycemic agent of choice.
There was widespread agreement that PTDM-related
risks should be addressed in conjunction with other
cardio-metabolic risk factors to reduce cardiovascular
disease posttransplantation as comprehensively reviewed
elsewhere (54).
Recommendation 7: Expand Basic,
Translational and Clinical Research in the
Field of PTDM to Resolve Unanswered
Questions
Although our understanding of PTDMhas been significantly
enhanced over the last decade, continued research is
essential to develop our clinical evidence base. The
consensus group recommended greater emphasis on
basic, translational and clinical research to resolve unan-
swered questions. Table 2 highlights studies currently in
progress (as registered on clinicaltrials.org) in the field of
PTDM and further targeted studies should be encouraged.
From a practical standpoint, there is a need to collaborate
and combine data linking fasting/postprandial glucose and
HbA1cwith end points including patient/graft survival, rates
of malignancy, cardiovascular events and microvascular
complications (such as retinopathy). Long-term complica-
tions relating to different glycemic indicators (e.g. HbA1c
vs. 2-h glucose) are warranted. Shedding light on molecular
mechanisms by which immunosuppressants affect beta
cell function and insulin resistance could provide deeper
insight into the pathophysiology and progression of
PTDM, thus preexisting experimental models should be
enhanced (55) and ‘‘omics’’ technology explored. From a
clinical standpoint, trials to improve prediction of PTDM
and delay or prevent PTDM are needed, including most
appropriate risk factors to screen as part of routine clinical
practice. We also need to determine whether improving
glycemic control, especially early insulin treatment,
improves long-term outcomes. Toward the latter aim we
hope to facilitate clinical trials of PTDM prevention and
management (pharmacological and/or nonpharmacological
therapies), which are adequately powered to relevant end
points such as cardiovascular events and mortality.
Conclusions
This Meeting Report summarizes opinion-based recom-
mendations from the recently convened International
Expert Panel review of PTDM and constitutes an overdue
update to previous consensus guidance. Our recommen-
dations, GRADE defined based upon expert opinion, reflect
the perspective and knowledge acquired over the last
decade and represents consensus from clinicians and
researchers with active interest and expertise in the field.
Our recommendations represent significant changes in
practice and include: terminology revision from NODAT to
PTDM, exclusion of transient posttransplant hyperglycemia
from PTDM diagnosis, expansion of screening strategies
(incorporating postprandial glucose and HbA1c) and opin-
ion-based guidance regarding pharmacological therapy in
light of recent clinical evidence.
Given the overall improvement in other areas of transplan-
tation, PTDM now constitutes one of the most important
complications associated with transplantation, associated
with significant morbidity and mortality. The consensus
group plan to submit updated guidelines encompassing and
elaborating upon our opinion-based recommendations and
intends to revise these recommendations in 3–5 years,with
the anticipated benefit of new data and research.
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